Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2020 Mar 23;15(1):69.
doi: 10.1186/s13014-020-01510-w.

1.5 T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment

Filippo Alongi  1   2 , Michele Rigo  3 , Vanessa Figlia  3 , Francesco Cuccia  3 , Niccolò Giaj-Levra  3 , Luca Nicosia  3 , Francesco Ricchetti  3 , Gianluisa Sicignano  3 , Antonio De Simone  3 , Stefania Naccarato  3 , Ruggero Ruggieri  3 , Rosario Mazzola  3
Affiliations
Observational Study

1.5 T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment

Filippo Alongi et al. Radiat Oncol. .

Abstract

Background: Unity Elekta is a unique magnetic resonance (MR)-linac that conjugates a 1.5 Tesla MR unit with a 7 MV flattening filter free accelerator.A prospective observational study for the clinical use of Elekta Unity is currently ongoing in our department. Herein, we present our preliminary report on the feasibility, quality of life, and patient-reported outcomes measures (PROMs) for localized prostate cancer (PC) treated with stereotactic body radiotherapy (SBRT).

Methods: The SBRT protocol consisted of a 35 Gy schedule delivered in 5 fractions within 2 weeks. Toxicity and quality of life (QoL) were assessed at baseline and after treatment using the Common Terminology Criteria for Adverse Events v5.0, International Prostatic Symptoms Score (IPSS), ICIQ-SF, IIEF-5, and EORTC-QLQ-C30 and PR-25 questionnaires.

Results: Between October 2019 and January 2020, 25 patients with localized PC were recruited. The median age was 68 years (range, 54-82); 4 were low risk, 11 favorable intermediate risk (IR) and 10 unfavorable IR. Median iPSA was 6.8 ng/ml (range, 1-19), and 9 of these patients (36%) received concurrent androgen deprivation therapy. Median prostate volume was 36 cc (range, 20-61); median baseline IPSS was 5 (range, 0-10). Median time for fraction was 53 min (range, 34-86); adaptive strategy with daily critical structure and target re-contouring and daily replanning (adapt to shape) was performed in all cases. No grade ≥ 3 adverse event was observed, three patients (12%) reported grade 2 acute genitourinary toxicity (urinary frequency, urinary tract pain and urinary retention), while only one patient reported mild rectal pain. No relevant deteriorations were reported in PROMs.

Conclusion: To the best of our knowledge, this is the first experience reporting feasibility, clinician-reported outcome measurements, and PROMs for 1.5 T MR-guided adaptive SBRT for localized prostate cancer. The preliminary data collected here report optimal safety and excellent tolerability, as also confirmed by PROMs questionnaires. Moreover, the data on technical feasibility and timing of online daily adapted planning and delivery are promising. More mature data are warranted.

Trial registration: Date of approval April 2019 and numbered MRI/LINAC n°23,748.

Keywords: Adaptive radiotherapy; MRI-guided radiotherapy; Prostate cancer; QoL; SBRT.

PubMed Disclaimer

Conflict of interest statement

FA acts as Elekta consultant and he had speaker honoraria. The remaining authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
International Prostate Symptom Score (IPSS)
Fig. 2
Fig. 2
Quality of Life Questionnaire for Patients with Prostate Cancer (EORTC QLQ-PR25)
Fig. 3
Fig. 3
Expanded Prostate Cancer Index Composite-26 (EPIC-26)
Fig. 4
Fig. 4
EORTC Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Fig. 5
Fig. 5
Panel left: International Index of Erectile Function – 5 (IIEF-5). Panel right: International Consultation on Incontinence Questionnaire- Short Form (ICIQ-SF)
See this image and copyright information in PMC

References

    1. Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate Cancer. N Engl J Med. 2016;375:1415–1424. doi: 10.1056/NEJMoa1606220. - DOI - PubMed
    1. Neal DE, Metcalfe C, Donovan JL, Lane JA, Davis M, Young GJ, et al. Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received Eur Urol. 2019. doi: 10.1016/j.eururo.2019.10.030. - PubMed
    1. Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E, et al. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate Cancer. N Engl J Med. 2016;375(15):1425–1437. doi: 10.1056/NEJMoa1606221. - DOI - PMC - PubMed
    1. Cuccia F, Mazzola R, Arcangeli S, Mortellaro G, Figlia V, Caminiti G, et al. Moderate hypofractionated helical tomotherapy for localized prostate cancer: preliminary report of an observational prospective study. Tumori. 2019;105(6):516–523. doi: 10.1177/0300891619867846. - DOI - PubMed
    1. Fersino S, Tebano U, Mazzola R, Giaj-Levra N, Ricchetti F, Di Paola G, et al. Moderate Hypofractionated Postprostatectomy volumetric modulated arc therapy with daily image guidance (VMAT-IGRT): a mono-institutional report on feasibility and acute toxicity. Clin Genitourin Cancer. 2017;15(4):e667–e673. doi: 10.1016/j.clgc.2017.01.025. - DOI - PubMed

Publication types